R James Breitmeyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […] ....

City Of , United Kingdom , Salim Yazji , James Breitmeyer , Carl Byrnes , Matthew Smith , Evan Yu , Fred Hutch , Richard Vincent , Professor Johann De Bono , Mass General , Northland Capital , Nanotechnology Stocks To Buy , Performing Dividend , Oncternal Therapeutics , R James Breitmeyer , Salim Yazji , Prostate Cancer , Perator Instructions , Forward Looking Statements , Dose Escalation Study , James Breitmeyer , Financial Results Conference ,